(Q84668296)

English

Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer

scientific article published on 02 August 2011

In more languages
default for all languages
No label defined

No description defined

Statements

Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer (English)

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit